IL99759A - Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them - Google Patents

Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL99759A
IL99759A IL99759A IL9975991A IL99759A IL 99759 A IL99759 A IL 99759A IL 99759 A IL99759 A IL 99759A IL 9975991 A IL9975991 A IL 9975991A IL 99759 A IL99759 A IL 99759A
Authority
IL
Israel
Prior art keywords
aminoindan
propargyl
mono
preparation
pharmaceutical compositions
Prior art date
Application number
IL99759A
Other languages
English (en)
Other versions
IL99759A0 (en
Inventor
Sterling Jeff
Levy Ruth
Veinberg Alex
Goldenberg Willy
Finberg John
Youdim Musa
Gutman Arieh
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL11281991A priority Critical patent/IL112819A/en
Priority to IL99759A priority patent/IL99759A/xx
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL99759A0 publication Critical patent/IL99759A0/xx
Priority to AU26063/92A priority patent/AU649565B2/en
Priority to ZA927570A priority patent/ZA927570B/xx
Priority to FI924458A priority patent/FI113262B/fi
Priority to NZ244616A priority patent/NZ244616A/en
Priority to CA002079968A priority patent/CA2079968C/en
Priority to HU9203162A priority patent/HU217589B/hu
Priority to CN92113070A priority patent/CN1038928C/zh
Priority to ES92402821T priority patent/ES2101063T3/es
Priority to EP92402821A priority patent/EP0538134B1/de
Priority to DK92402821.0T priority patent/DK0538134T3/da
Priority to AT92402821T priority patent/ATE149999T1/de
Priority to JP27731492A priority patent/JP3247165B2/ja
Priority to DE69218101T priority patent/DE69218101T2/de
Priority to US08/310,480 priority patent/US5486541A/en
Priority to GR970401207T priority patent/GR3023556T3/el
Publication of IL99759A publication Critical patent/IL99759A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL99759A 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them IL99759A (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
AU26063/92A AU649565B2 (en) 1991-10-16 1992-09-30 Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
ZA927570A ZA927570B (en) 1991-10-16 1992-10-01 Mono-fluorinated derivatives of N-propagyl-1-aminoindan and their use as inhibitors of monoamine oxidase.
FI924458A FI113262B (fi) 1991-10-16 1992-10-02 Menetelmä N-propargyyli-1-aminoindaanin fluorattujen johdannaisten valmistamiseksi
NZ244616A NZ244616A (en) 1991-10-16 1992-10-05 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, preparation and pharmaceutical compositions thereof
CA002079968A CA2079968C (en) 1991-10-16 1992-10-06 Mono-fluorinated derivatives of n-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
HU9203162A HU217589B (hu) 1991-10-16 1992-10-06 N-propargil-1-amino-indán monofluorszármazékai és ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek és a gyógyászati készítmények előállítására
CN92113070A CN1038928C (zh) 1991-10-16 1992-10-14 制备单氟化的n－炔丙基－1－氨基茚满衍生物的方法
ES92402821T ES2101063T3 (es) 1991-10-16 1992-10-15 Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa.
DE69218101T DE69218101T2 (de) 1991-10-16 1992-10-15 Monofluorierte Derivate von N-Propargyl-1-Aminoindan und deren Verwendung als Monoamino-Oxidaseinhibitoren
EP92402821A EP0538134B1 (de) 1991-10-16 1992-10-15 Monofluorierte Derivate von N-Propargyl-1-Aminoindan und deren Verwendung als Monoamino-Oxidaseinhibitoren
DK92402821.0T DK0538134T3 (da) 1991-10-16 1992-10-15 Monofluorerede derivater af N-propargyl-1-aminoindan og deres anvendelse som inhibitorer for monoaminoxidase
AT92402821T ATE149999T1 (de) 1991-10-16 1992-10-15 Monofluorierte derivate von n-propargyl-1- aminoindan und deren verwendung als monoamino- oxidaseinhibitoren
JP27731492A JP3247165B2 (ja) 1991-10-16 1992-10-15 Ｎ−プロパルギル−１−アミノインダンのモノ−弗素化誘導体、これを有効成分とする薬剤およびその製造方法
US08/310,480 US5486541A (en) 1991-10-16 1994-09-22 Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
GR970401207T GR3023556T3 (en) 1991-10-16 1997-05-26 Mono-fluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL99759A0 IL99759A0 (en) 1992-08-18
IL99759A true IL99759A (en) 1997-06-10

Family

ID=11062970

Family Applications (2)

Application Number Title Priority Date Filing Date
IL99759A IL99759A (en) 1991-10-16 1991-10-16 Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL11281991A IL112819A (en) 1991-10-16 1991-10-16 Fluorinated 1-aminoindan compounds and a process for their preparation

Country Status (16)

Country Link
US (1) US5486541A (de)
EP (1) EP0538134B1 (de)
JP (1) JP3247165B2 (de)
CN (1) CN1038928C (de)
AT (1) ATE149999T1 (de)
AU (1) AU649565B2 (de)
CA (1) CA2079968C (de)
DE (1) DE69218101T2 (de)
DK (1) DK0538134T3 (de)
ES (1) ES2101063T3 (de)
FI (1) FI113262B (de)
GR (1) GR3023556T3 (de)
HU (1) HU217589B (de)
IL (2) IL99759A (de)
NZ (1) NZ244616A (de)
ZA (1) ZA927570B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
WO1995004713A1 (en) * 1993-08-06 1995-02-16 The Upjohn Company 2-aminoindans as selective dopamine d3 ligands
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0738149B1 (de) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6211235B1 (en) 1996-11-22 2001-04-03 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
DE69738275T2 (de) 1996-12-18 2008-08-28 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
US6635632B1 (en) * 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
IL149308A0 (en) 1999-10-27 2002-11-10 Teva Pharma Use of 1-aminoindan derivatives for treatment of manic disorders
WO2001083425A1 (en) * 2000-05-04 2001-11-08 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
US6956129B2 (en) 2001-02-16 2005-10-18 Bayer Aktiengesellschaft Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
EP1567152B1 (de) * 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Verwendung von rasagilin mit riluzol zur behandlung der amyotrophenlateralsklerose
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US8097608B2 (en) 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
US20080090915A1 (en) * 2003-11-25 2008-04-17 Technion Research And Development Foundation Ltd. Method for preventing or attenuating anthracycline-induced cardiotoxicity
EP1686973A4 (de) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation Zusammensetzungen und verfahren zur behandlung von kardiovaskulären erkrankungen und krankheiten
EP1778196A4 (de) * 2004-07-26 2008-12-17 Teva Pharma Pharmazeutische dosierungsformen mit rasagilin
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
HRP20130622T1 (en) * 2005-02-17 2013-08-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2901244A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
AU2006252540B2 (en) * 2005-06-02 2011-12-01 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CN103142570A (zh) 2005-12-09 2013-06-12 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil 用于神经保护的用途
EP1991214B1 (de) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Verwendung von rasagilin zur behandlung von multipler systematrophie
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
EP2007369A4 (de) * 2006-04-03 2009-07-01 Teva Pharma Verwendung von rasagilin zur behandlung des syndroms der ruhelosen beine
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) * 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
RS52183B (sr) * 2006-12-14 2012-10-31 Teva Pharmaceutical Industries, Ltd. Kristalna čvrsta baza razagilina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2053033A1 (de) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Verbindungen zur Verwendung bei der Abbildung, Diagnose und/oder Behandlung von Erkrankungen des zentralen Nervensystems oder von Tumoren
WO2009089049A1 (en) * 2008-01-11 2009-07-16 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations, their preparation and use
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
CN102264689B (zh) * 2008-12-22 2014-12-31 新梅斯托克尔卡公司 制备伊伐布雷定的方法
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2515891A4 (de) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-n-propargyl-1-aminoindan
CN102791258B (zh) 2010-02-03 2018-05-08 图必制药公司 雷沙吉兰的延长释放制剂及其用途
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
HK1200314A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceuticals Usa, Inc. R(+)-n-methyl-propargyl-aminoindan
HK1200315A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB1033686A (en) * 1965-05-10 1966-06-22 Maximilian Heller Improvements in convertible double bed settees
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2079968C (en) 2004-12-21
DK0538134T3 (da) 1997-04-01
EP0538134B1 (de) 1997-03-12
JPH05262701A (ja) 1993-10-12
EP0538134A3 (en) 1993-06-16
AU649565B2 (en) 1994-05-26
US5486541A (en) 1996-01-23
ES2101063T3 (es) 1997-07-01
CA2079968A1 (en) 1993-04-17
ZA927570B (en) 1993-04-14
AU2606392A (en) 1993-04-22
DE69218101D1 (de) 1997-04-17
EP0538134A2 (de) 1993-04-21
IL112819A (en) 2001-11-25
FI924458L (fi) 1993-04-17
DE69218101T2 (de) 1997-09-25
IL99759A0 (en) 1992-08-18
ATE149999T1 (de) 1997-03-15
CN1038928C (zh) 1998-07-01
FI924458A0 (fi) 1992-10-02
CN1073427A (zh) 1993-06-23
FI113262B (fi) 2004-03-31
NZ244616A (en) 1995-04-27
HU9203162D0 (en) 1992-12-28
JP3247165B2 (ja) 2002-01-15
HUT67218A (en) 1995-03-28
HU217589B (hu) 2000-02-28
GR3023556T3 (en) 1997-08-29

Similar Documents

Publication Publication Date Title
AU3544593A (en) New naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
AU1608692A (en) Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants
AU673893B2 (en) New pyridothiadiazones, processes for their preparation and the pharmaceutical compositions which contain them
IL112622A0 (en) Camptothecin derivatives, their preparation and pharmaceutical compositions containing them
HUT73529A (en) New bis-naphthalimides for the treatment of cancer
TW252979B (de)
AU3559793A (en) New 3-aminochroman spiro compounds, processes for their preparation and pharmaceutical compositions containing them
GR3017348T3 (en) Novel isoindolinone derivative, preparation thereof, and pharmaceutical compositions containing same.
AU654300B2 (en) 7-acyl-3-(substituted carbamoyloxy)cephem compounds and process for their preparation
IL100955A (en) Amino-polyhydroxy- cyclopentane derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
GR3017599T3 (en) Thiochromane derivatives, process for their preparation and pharmaceutical compositions containing them.
AU6970394A (en) Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2
HK27096A (en) Benzofuranylimidazole derivatives
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
ES2027507A6 (es) Procedimiento de preparacion de derivados selenofenicos.
AU5511394A (en) New (cyclohexyl)alkene compounds, processes for preparing them and pharmaceutical compositions containing them
AU4965593A (en) Ureido-acetamide derivatives, preparation thereof and drugs containing same
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
HUT68015A (en) New compound leustroducsin h, its preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees